GENEDX HOLDINGS CORP.

NASDAQ: WGS (GeneDx Holdings Corp.)

Kemas kini terakhir: 29 Nov, 7:22PM

166.95

1.34 (0.81%)

Penutupan Terdahulu 165.61
Buka 165.21
Jumlah Dagangan 158,702
Purata Dagangan (3B) 529,790
Modal Pasaran 4,825,620,992
Harga / Pendapatan (P/E TTM) 1,391.25
Harga / Pendapatan (P/E Ke hadapan) 238.10
Harga / Jualan (P/S) 11.20
Harga / Buku (P/B) 15.71
Julat 52 Minggu
55.17 (-66%) — 170.75 (2%)
Tarikh Pendapatan 28 Oct 2025
Margin Keuntungan -11.69%
Margin Operasi (TTM) -5.22%
EPS Cair (TTM) -1.39
Pertumbuhan Hasil Suku Tahunan (YOY) 39.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 44.61%
Nisbah Semasa (MRQ) 3.25
Aliran Tunai Operasi (OCF TTM) -1.90 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 17.79 M
Pulangan Atas Aset (ROA TTM) -1.84%
Pulangan Atas Ekuiti (ROE TTM) -16.61%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Diagnostics & Research (US) Menaik Bercampur
Diagnostics & Research (Global) Menaik Bercampur
Stok GeneDx Holdings Corp. Menaik Menaik

AISkor Stockmoo

-1.3
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam -4.0
Volatiliti Harga -5.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 4.0
Purata -1.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
WGS 5 B - 1,391.25 15.71
SHC 5 B - 87.40 8.64
TWST 2 B - - 4.02
NEOG 1 B - - 0.610
CSTL 1 B - - 2.44
CDNA 935 M - 13.72 3.06

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.

Sektor Healthcare
Industri Diagnostics & Research
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 12.56%
% Dimiliki oleh Institusi 102.71%

Pemilikan

Nama Tarikh Syer Dipegang
Oracle Investment Management Inc 30 Sep 2025 889,954
Julat 52 Minggu
55.17 (-66%) — 170.75 (2%)
Julat Harga Sasaran
140.00 (-16%) — 170.00 (1%)
Tinggi 170.00 (Guggenheim, 1.83%) Beli
Median 160.00 (-4.16%)
Rendah 140.00 (Wells Fargo, -16.14%) Pegang
140.00 (Piper Sandler, -16.14%) Beli
Purata 155.00 (-7.16%)
Jumlah 4 Beli, 1 Pegang
Harga Purata @ Panggilan 132.13
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wells Fargo 04 Nov 2025 140.00 (-16.14%) Pegang 139.49
BTIG 29 Oct 2025 165.00 (-1.17%) Beli 131.76
22 Oct 2025 140.00 (-16.14%) Beli 121.01
Canaccord Genuity 29 Oct 2025 160.00 (-4.16%) Beli 131.76
20 Oct 2025 155.00 (-7.16%) Beli 127.03
Guggenheim 29 Oct 2025 170.00 (1.83%) Beli 131.76
Piper Sandler 11 Sep 2025 140.00 (-16.14%) Beli 125.89
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
FEELEY KEVIN - 163.61 -377 -61,681
RUCH JOSHUA - 161.08 -38,000 -6,121,040
Jumlah Keseluruhan Kuantiti Bersih -38,377
Jumlah Keseluruhan Nilai Bersih ($) -6,182,721
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 162.35
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
FEELEY KEVIN Pegawai 01 Dec 2025 Jual (-) 377 163.61 61,681
FEELEY KEVIN Pegawai 01 Dec 2025 Pelaksanaan pilihan 717 - -
RUCH JOSHUA Pengarah 24 Nov 2025 Jual (-) 38,000 161.08 6,121,040
Tarikh Jenis Butiran
06 Nov 2025 Pengumuman GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
04 Nov 2025 Pengumuman GeneDx to Participate in Upcoming Investor Conferences
28 Oct 2025 Pengumuman GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
27 Oct 2025 Pengumuman GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
22 Oct 2025 Pengumuman GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
20 Oct 2025 Pengumuman GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
15 Oct 2025 Pengumuman Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
14 Oct 2025 Pengumuman GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
13 Oct 2025 Pengumuman GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
09 Oct 2025 Pengumuman GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
08 Oct 2025 Pengumuman GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
07 Oct 2025 Pengumuman GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
01 Oct 2025 Pengumuman GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
30 Sep 2025 Pengumuman GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
25 Sep 2025 Pengumuman GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
18 Sep 2025 Pengumuman GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda